Opus Genetics (IRD)
NASDAQ:IRD
Total Valuation
Opus Genetics has a market cap or net worth of $309.50M. The enterprise value is $264.41M.
Market Cap$309.50M
Enterprise Value$264.41M
Share Statistics
Opus Genetics has 71,149,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,149,050
Owned by Insiders18.31%
Owned by Institutions26.00%
Financial Efficiency
Opus Genetics’s return on equity (ROE) is -3.23 and return on invested capital (ROIC) is -90.90%.
Return on Equity (ROE)-3.23
Return on Assets (ROA)-0.99
Return on Invested Capital (ROIC)-90.90%
Return on Capital Employed (ROCE)-0.91
Revenue Per Employee788.67K
Profits Per Employee-2.76M
Employee Count18
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Opus Genetics is ―. Opus Genetics’s PEG ratio is 0.40.
PE Ratio―
PS Ratio88.10
PB Ratio81.49
Price to Fair Value81.49
Price to FCF-35.48
Price to Operating Cash Flow-76.78
PEG Ratio0.40
Income Statement
In the last 12 months, Opus Genetics had revenue of 14.20M and earned -49.59M in profits. Earnings per share was -0.80.
Revenue14.20M
Gross Profit14.14M
Operating Income-38.60M
Pretax Income-49.59M
Net Income-49.59M
EBITDA-38.60M
Earnings Per Share (EPS)-0.80
Cash Flow
In the last 12 months, operating cash flow was -35.25M and capital expenditures 0.00, giving a free cash flow of -35.25M billion.
Operating Cash Flow-35.25M
Free Cash Flow-35.25M
Free Cash Flow per Share-0.50
Dividends & Yields
Opus Genetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change343.43%
50-Day Moving Average3.67
200-Day Moving Average2.12
Relative Strength Index (RSI)50.61
Average Volume (3m)995.32K
Important Dates
Opus Genetics upcoming earnings date is May 8, 2026, After Close (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateMay 8, 2026
Ex-Dividend Date―
Financial Position
Opus Genetics as a current ratio of 6.43, with Debt / Equity ratio of 0.00%
Current Ratio6.43
Quick Ratio6.43
Debt to Market Cap0.00
Net Debt to EBITDA1.17
Interest Coverage Ratio-26.33
Taxes
In the past 12 months, Opus Genetics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Opus Genetics EV to EBITDA ratio is -31.23, with an EV/FCF ratio of -34.20.
EV to Sales84.92
EV to EBITDA-31.23
EV to Free Cash Flow-34.20
EV to Operating Cash Flow-34.20
Balance Sheet
Opus Genetics has $45.09M in cash and marketable securities with $0.00 in debt, giving a net cash position of $45.09M billion.
Cash & Marketable Securities$45.09M
Total Debt$0.00
Net Cash$45.09M
Net Cash Per Share$0.63
Tangible Book Value Per Share$0.02
Margins
Gross margin is 57.40%, with operating margin of -271.90%, and net profit margin of -349.33%.
Gross Margin57.40%
Operating Margin-271.90%
Pretax Margin-349.33%
Net Profit Margin-349.33%
EBITDA Margin-271.90%
EBIT Margin-271.90%
Analyst Forecast
The average price target for Opus Genetics is $9.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.71
Price Target Upside123.32% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast74.60%
EPS Growth Forecast-58.14%